Search Results 391-400 of 17719 for SC

  1. Publications - Joseph P. Grande, M.D., Ph.D. - Mayo Clinic

    ... SC, Lerman LO. Microvascular remodeling and altered angiogenic signaling in human kidneys distal to occlusive atherosclerotic renal artery stenosis. Nephrol ...

  2. Lupus - Symptoms & causes - Mayo Clinic

    This is called an autoimmune condition. Lupus causes swelling and irritation, called inflammation, that may affect joints, skin, kidneys, blood cells, brain, ...

  3. Publications - Richard D. Beegle, M.D. - Mayo Clinic

    Beegle RD, Dodson SC, Murray JV. Dysplastic cerebellar gangliocytoma RSNA Case Collection. 2020. Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, ...

  4. Nonalcoholic Fatty Liver Disease Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess the pharmacodynamics (PD) of HM15211 after administration of multiple subcutaneous (SC) doses compared to placebo on ...

  5. Get Started - Mayo Clinic

    This content does not have an Arabic version. Skip to content. Mayo ... SC: Mayo Clinic Breadcrumb. Home · Complex Care Program. Sections Complex Care ...

  6. Clinical trials - Oncology (Medical)

    SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve ...

  7. Adenocarcinoma Clinical Trials - Mayo Clinic Research

    This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC ...

  8. Publications - Claire Tiger, M.D., Ph.D. - Mayo Clinic

    Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma Cancers. 2024; 16(17):2931. McKenna M, Ryu Tiger YK, Rutherford SC, ...

  9. Safety, Efficacy And Tolerability Of Ianalumab Versus Placebo, Combination With SoC Therapy, In Participants With Active Lupus Nephritis - Mayo Clinic

    About this study. This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks ...

  10. Publications - Ming Yang, M.D. - Mayo Clinic

    Rolak SC, Frazier RD, Harris LA, Lunsford T, Yang M, Hasler WL. Regional gut transit delays on glucagon-like peptide-1 agonists in relation to clinical and ...